Last reviewed · How we verify
NCT04714086
Expanded Access Program for Avapritinib
trial testing Avapritinib in Solid Tumors. No longer available.
Quick facts
| Lead sponsor | Blueprint Medicines Corporation |
|---|---|
| Status | NO LONGER AVAILABLE |
| Study type | EXPANDED_ACCESS |
Drugs / interventions tested
- Avapritinib (AVAPRITINIB) — full drug profile →
Conditions studied
- Solid Tumors — all drugs for Solid Tumors →
Sponsor
Blueprint Medicines Corporation — full company profile →
Who can join
18 and older, any sex, with Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This record comprises the currently available Expanded Access Programs (EAP) for avapritinib (BLU-285): 1\) A Post Trial Access (PTA) program to provide continued access to treatment with avapritinib to BLU-285-1107 participants with solid tumors who are unable to access commercially available avapritinib after trial BLU-285-1107 (NCT04908176) has ended.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04714086
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Avapritinib
Trials testing the same drug.
- NCT07255638 — A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · recruiting
- NCT06765915 — Avapritinib Maintenance for AML With KIT Mutations · Phase 2 · not yet recruiting
- NCT06748001 — Avapritinib Rollover Study · Phase 4 · recruiting
- NCT07131059 — MRD-positive AML Clinical Study · NA · recruiting
- NCT05381753 — Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World · completed
Other recruiting trials for Solid Tumors
Currently open trials in the same condition.
- NCT07529002 — Clinical Application of 89Zr-s-C1 PET/CT Imaging in Solid Tumors · recruiting
- NCT07416123 — A Study of GEN1106 in Participants With Solid Tumors · Phase 1 · recruiting
- NCT07522073 — A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancre · Phase 3 · recruiting
- NCT07395258 — A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Differe · Phase 1 · recruiting
- NCT07505069 — Exploring the Clinical Value of RT01-89Zr PET Imaging in Solid Tumors · EARLY_PHASE1 · recruiting
Other Blueprint Medicines Corporation trials
Trials by the same sponsor.
- NCT07388511 — A Study of Elenestinib in Healthy Adult Female Participants · Phase 1 · recruiting
- NCT07264959 — An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM) · not yet recruiting
- NCT07255638 — A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany · recruiting
- NCT07143669 — Screening Study for KIT D816V Mutated Mast Cell Disease in Select Populations · recruiting
- NCT06931405 — Study of BLU-808 in Chronic Inducible Urticaria (CIndU) and Chronic Spontaneous Urticaria (CSU) · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04714086 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Blueprint Medicines Corporation
- Last refreshed: 24 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04714086.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing